Amgen Acquires Dark Blue to Advance Novel AML Treatments

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The transaction strengthens Amgen’s oncology research pipeline and underscores its continued focus on developing innovative therapies for cancers with significant unmet medical needs, particularly acute myeloid leukemia (AML).

Dark Blue Therapeutics is developing first-in-class small molecule targeted protein degraders designed to address cancer-driving proteins that have historically been difficult to target. Through the acquisition, Amgen gains an investigational small molecule program aimed at degrading two related proteins, MLLT1 and MLLT3, which are known to play a key role in certain subtypes of AML. AML is an aggressive and fast-progressing blood cancer that remains challenging to treat, with high relapse rates and limited long-term survival for many patients.

According to Amgen, preclinical data from leukemia models have shown promising anti-cancer activity for the Dark Blue investigational compound. The data also suggest mechanistic differentiation from existing therapies, supporting its potential use both as a single agent and in combination with other treatments. This approach could help overcome treatment resistance and improve the durability of remission, two major hurdles in AML care.

Jay Bradner, M.D., executive vice president of Research and Development at Amgen, said the acquisition reflects the company’s commitment to investing early in innovative science. He noted that AML continues to be one of the most difficult cancers to treat and emphasized the need for new therapeutic mechanisms that can meaningfully change patient outcomes. Bradner added that the Dark Blue program aligns closely with Amgen’s expertise in cancer biology and targeted protein degradation, positioning the asset well for rapid advancement into clinical investigation.

Following the transaction, Amgen plans to integrate Dark Blue Therapeutics into its existing research organization. The move is expected to bolster Amgen’s early-stage oncology discovery efforts and expand its capabilities in targeted protein degradation, an emerging area of drug development with the potential to address previously undruggable targets.

Overall, the acquisition highlights Amgen’s strategy to build a diversified and innovative oncology pipeline by combining internal research with targeted external investments, with the goal of delivering new treatment options for patients facing serious and life-threatening cancers such as AML.